A comparison of two pancreatin microsphere preparations in cystic fibrosis
- PMID: 1553114
A comparison of two pancreatin microsphere preparations in cystic fibrosis
Abstract
Objectives: to compare the efficacy and tolerance of Creon and Pancrease in children and young adults with cystic fibrosis.
Methods: a double blind, crossover study of two pH sensitive microsphere preparations of pancreatin (Creon, Pancrease), given in equivalent lipase dosage to 27 children with cystic fibrosis, was conducted.
Results: at similar lipase activity no significant difference was found in the following: coefficient of fat absorption (CFA), coefficient of nitrogen absorption (CNA), weight gain, mean adequate daily intake for energy, and subjective symptoms. Three children who had a CFA less than 70% while receiving Pancrease all improved on Creon. No children had a CFA less than 70% while receiving Creon. A significant reduction in the number of capsules required daily to achieve similar control was possible when changing from Pancrease (mean 25/day) to Creon (mean 15/day). Seventy percent of patients preferred Creon and this was likely to be related to a perceived reduction in abdominal pain and stool frequency, and need for less capsules per day.
Conclusion: Creon and Pancrease are equally effective at doses providing equal lipase activity, however, the reduced number of capsules, fewer symptoms, and possible improvement of more severe steatorrhoea result in an increased patient preference for Creon.
Similar articles
-
Efficacy of pancreatic enzyme supplementation in children with cystic fibrosis: comparison of two preparations by random crossover study and a retrospective study of the same patients at two different ages.J Pediatr Gastroenterol Nutr. 1988;7 Suppl 1:S40-5. J Pediatr Gastroenterol Nutr. 1988. PMID: 3042938 Clinical Trial.
-
Comparative evaluation of a high lipase pancreatic enzyme preparation and a standard pancreatic supplement for treating exocrine pancreatic insufficiency in chronic pancreatitis.Eur J Gastroenterol Hepatol. 1996 Jul;8(7):699-703. Eur J Gastroenterol Hepatol. 1996. PMID: 8853261 Clinical Trial.
-
Comparison of four pancreatic extracts in cystic fibrosis.Arch Dis Child. 1987 Jun;62(6):564-8. doi: 10.1136/adc.62.6.564. Arch Dis Child. 1987. PMID: 3304172 Free PMC article. Clinical Trial.
-
[Comparative study of the effect of kreon and cotazyme forte in children with cystic fibrosis].Orv Hetil. 1988 May 8;129(19):995-9. Orv Hetil. 1988. PMID: 3290773 Review. Hungarian. No abstract available.
-
Current concepts: pancreatic extracts.N Engl J Med. 1969 Jul 24;281(4):201-4. doi: 10.1056/NEJM196907242810406. N Engl J Med. 1969. PMID: 4892805 Review. No abstract available.
Cited by
-
Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire.Front Pharmacol. 2023 Oct 25;14:1167407. doi: 10.3389/fphar.2023.1167407. eCollection 2023. Front Pharmacol. 2023. PMID: 38026920 Free PMC article.
-
Enzyme contents of pancreatic extract preparations. Are they optimal?Drugs. 1992 Nov;44(5):685-9. doi: 10.2165/00003495-199244050-00001. Drugs. 1992. PMID: 1280561 Review. No abstract available.
-
Pancreatic enzyme replacement therapy for people with cystic fibrosis.Cochrane Database Syst Rev. 2020 Aug 5;8(8):CD008227. doi: 10.1002/14651858.CD008227.pub4. Cochrane Database Syst Rev. 2020. PMID: 32761612 Free PMC article.
-
Control of malabsorption in cystic fibrosis.Paediatr Drugs. 2000 May-Jun;2(3):205-22. doi: 10.2165/00128072-200002030-00005. Paediatr Drugs. 2000. PMID: 10937471 Review.
-
Scoring Abdominal Symptoms in People with Cystic Fibrosis.J Clin Med. 2024 Mar 13;13(6):1650. doi: 10.3390/jcm13061650. J Clin Med. 2024. PMID: 38541878 Free PMC article. Review.